N-c(=x)x Containing (x Is Chalcogen) Doai Patents (Class 514/476)
  • Publication number: 20040171678
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: February 25, 2004
    Publication date: September 2, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6774180
    Abstract: High molecular weight derivatives of activated poly(ethylene glycol) and the like polymers are prepared in high purity by conjugating a large PEG molecule to a small PEG molecule. Most of the reaction steps can be accomplished on the more readily purified small molecule to avoid laborious purification of the high molecular weight derivatives.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: August 10, 2004
    Assignee: Nektar Therapeutics AL, Corporation
    Inventors: Antoni Kozlowski, Xiaoming Shen, Michael David Bentley, Zhihao Fang
  • Patent number: 6765021
    Abstract: This invention provides compounds of formula I having the structure wherein: B, D, C, and R1 as defined herein.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: July 20, 2004
    Assignee: Wyeth
    Inventors: John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa Marie Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt
  • Publication number: 20040138176
    Abstract: The invention relates to a compositions useful in the field of agricultural chemistry and methods for making and using the compositions. The compositions include (i) a permeabilizing agent, and (ii) a active component, for example, a pesticide or plant growth regulator, and can include additional components as well, for example, flow agents. The permeabilizing agent, or a mixture of permeabilizing agents, acts as an adjuvant to the active component or chemicals to improve the degree of efficacy of the active component or speed of action of the active component. The permeabilizing agents are typically one or more chelating agents, cationic materials, anionic materials, and zwitterionic materials, and include polyphosphate salts. Examples of cationic materials include polyamines such as ethylenediamine and quaternary ammonium salts. The active components can be pesticides, herbicides, insecticides, fungicides, virucides, bacteriocides, and acaricides.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 15, 2004
    Applicant: CJB Industries, Inc.
    Inventor: David Miles
  • Patent number: 6730700
    Abstract: Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: May 4, 2004
    Assignee: Renovis, Inc.
    Inventors: L. David Waterbury, Allan L. Wilcox, John M. Carney, Farah Mavandadi, Albert Danielzadeh
  • Publication number: 20040039039
    Abstract: Fungicidal mixtures, comprising
    Type: Application
    Filed: July 3, 2003
    Publication date: February 26, 2004
    Inventors: Arne Ptock, Eberhard Ammermann, Reinhard Stierl, Gisela Lorenz, Siegried Strathmann, Maria Scherer, Klaus Schelberger, Achim Reddig
  • Patent number: 6696487
    Abstract: The invention relates to compounds of formula (I), and also to salts thereof, which have fungicidal activities: in which the various radicals and substituents are as defined in the description, and also to the fungicidal compositions containing them and to methods for combating the phytopathogenic fungi of crops using these compounds and compositions.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: February 24, 2004
    Assignee: Bayer Cropscience S.A.
    Inventors: Vincent Gerusz, Darren James Mansfield, José Perez, David Tickle, Jean-Pierre Vors, Derek Baldwin, Thomas Lawley Hough, Dale Robert Mitchell
  • Patent number: 6689774
    Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: February 10, 2004
    Assignee: Zinc Therapeutics, Canada Inc.
    Inventor: Henry Fliss
  • Publication number: 20040019103
    Abstract: A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II).
    Type: Application
    Filed: July 10, 2003
    Publication date: January 29, 2004
    Applicant: Biorex Research & Development Co.
    Inventors: Laszlo Vigh, Peter Literati Nagy, Jeno Szilbereky, Laszlo Urogdi, Andrea Jednakovits, Laszlo Jaszlits, Katalin Biro, Ede Marvanyos, Mihaly Barabas, Erzsebet Hegedus, Laszlo Koranyi, Maria Kurthy, Gabor Balogh, Ibolya Horvath, Zsolt Torok, Eva Udvardy, Gyorgy Dorman, Denes Medzihradszky, Bea Mezes, Eszter Kovacs, Erno Duda, Beatrix Farkas, Attila Glatz
  • Publication number: 20040019102
    Abstract: There is provided a method for inhibiting ATF/CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.
    Type: Application
    Filed: May 14, 2003
    Publication date: January 29, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6677308
    Abstract: The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;v&bgr;3 integrin.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: January 13, 2004
    Assignee: G. D. Searle & Co.
    Inventors: Nizal Chandrakumar, Michael Clare, Wendell Doubleday, Alan F. Gasiecki, Mark A. Russell
  • Patent number: 6673788
    Abstract: A class of compounds is described which can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula II: wherein each of R1, R2, and R3 is independently selected from hydrido, halo, and nitro; wherein R8 is selected from haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted arylalkoxy and optionally substituted aryloxyalkyl; wherein Y is selected from fluoroalkyl, and and wherein R9 is alkylamino; or a pharmaceutically-acceptable salt or tautomer thereof.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: January 6, 2004
    Assignee: G. D. Searle & Co.
    Inventors: Daniel L. Flynn, Jeffery Zablocki, Kenneth Williams, Susan L. Hockerman
  • Publication number: 20030229064
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: March 3, 2003
    Publication date: December 11, 2003
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6653309
    Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: November 25, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeffrey O. Saunders, Daniel Elbaum, Perry M. Novak, Douglas Naegele, Randy S. Bethiel, Steven M. Ronkin, Michael C. Badia, Catharine Frank, Dean P. Stamos, William Walters, David Pearlman
  • Patent number: 6649591
    Abstract: In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: November 18, 2003
    Assignee: Medinox, Inc.
    Inventor: Ching-San Lai
  • Publication number: 20030203887
    Abstract: In accordance with the present invention, there are provided methods for the in vivo reduction of free radical levels in mammalian subjects in need thereof. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the species responsible for free radical production is inhibited), the present invention employs a scavenging approach whereby overproduced free radical is bound in vivo to a suitable free radical scavenger. An exemplary free radical scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. This complex binds to free radicals, forming a stable, water-soluble free radical-containing complex. When administered to a subject afflicted with a disorder associated with free radical overproduction (e.g.
    Type: Application
    Filed: May 7, 2003
    Publication date: October 30, 2003
    Applicant: MCW Research Foundation, Inc.,
    Inventor: Ching-San Lai
  • Patent number: 6630509
    Abstract: The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, which compounds have utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: October 7, 2003
    Assignee: AstraZeneca AB
    Inventors: Jonas Fägerhag, Lanna Li, Eva-Lotte Lindstedt Alstermark
  • Publication number: 20030181495
    Abstract: The present invention provides novel combinations of dithiocarbamate disulfide dimers with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with a thiazolidinedione for the treatment of diabetes. In another embodiment, In another embodiment, invention combinations further comprise additional active agents such as, for example, metformin, insulin, sulfonylureas, and the like. In another embodiment, the present invention relates to compositions and formulations useful in such therapeutic methods.
    Type: Application
    Filed: March 21, 2003
    Publication date: September 25, 2003
    Applicant: Medinox, Inc.
    Inventors: Ching-San Lai, Vassil P. Vassilev
  • Patent number: 6620798
    Abstract: Methods for the repair, reconstruction and protection of tissue using compositions containing flavonoids and/or flavonols, including simultaneous administration of agents in order to obtain synergistic effects from the combinations taught and claimed herein. The administration of the flavonols and /or flavonoids in conjuction with compositions containing vitamin C and/or salts and esters of vitamin C provides advantageous sparing of autocoids (internal steroids). The simultaneous administration of flavonols and /or flavonoids to compositions containing glucosamine and or glucosamine sulfate and chondroitin stimulates rapid improvement in joint function. The addition to the flavonoids and/or flavonols to previously administered compositions is a most convenient method of achieving enhanced benefits. The use of combinations of flavonoids and flavonols for use in relieving pain is also a part of the invention.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: September 16, 2003
    Inventor: Russell Jaffe
  • Publication number: 20030134897
    Abstract: Compositions including an aromatic compound for inhibiting the production of exoproteins by Gram positive bacteria are disclosed.
    Type: Application
    Filed: October 2, 2001
    Publication date: July 17, 2003
    Applicant: Kimberly-Clark Worldwide, Inc.
    Inventors: Rae Ellen Syverson, Richard A. Proctor
  • Patent number: 6573297
    Abstract: A (2-substituted oxyphenyl)alkanamide derivative or a salt thereof expressed by the following Formula (I): wherein one of A and B is a hydrocarbon group of C3-30 expressed by R1 and the other is —(CH2)n-NR2R3; Z is —CO— or —CONR6—; R2 and R3 individually represent H, lower alkyl or benzyl, or —NR2R3 may be a heterocycle having 3-7 members; wherein —CONR5—(CH2)n-NR2R3 or —CONR6—(CH2)n-NR2R3 may be the following Group (II): wherein ring Y is a heterocycle of 6 or 7 members; R4 is selected from the group consisting of H, halogen, lower alkyl, lower acyl and etc; R5 and R6 are individually H, lower alkyl, lower acyl or lower alkylcarbamoyl, or may form a part of said Group(II); 1 is 0 or 1; m is 1 or 2; and n is an integer of 0-5.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: June 3, 2003
    Assignee: Shiseido Co., Ltd.
    Inventors: Koji Kobayashi, Hirotada Fukunishi, Tokuro Iwabuchi
  • Publication number: 20030087840
    Abstract: In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or “DC”) and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.
    Type: Application
    Filed: June 18, 2002
    Publication date: May 8, 2003
    Applicant: Medinox, Inc.
    Inventors: Ching-San Lai, Tingmin Wang
  • Patent number: 6548540
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 15, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20030065026
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide strongly inhibits the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: September 8, 1999
    Publication date: April 3, 2003
    Inventor: THOMAS P. KENNEDY
  • Patent number: 6534541
    Abstract: The present invention is in particular related to the use of rivastigmine in the manufacture of a medicament for the treatment of ocular disorders.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: March 18, 2003
    Assignee: Novartis AG
    Inventor: David Goldblum
  • Publication number: 20030040511
    Abstract: In accordance with the present invention, there are provided methods for the in vivo reduction of free radical levels in mammalian subjects in need thereof. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the species responsible for free radical production is inhibited), the present invention employs a scavenging approach whereby overproduced free radical is bound in vivo to a suitable free radical scavenger. An exemplary free radical scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. This complex binds to free radicals, forming a stable, water-soluble free radical-containing complex. When administered to a subject afflicted with a disorder associated with free radical overproduction, the water-soluble free radical-containing complex is produced and then filtered through the kidneys, concentrated in the urine, and eventually excreted by the subject, thereby reducing in vivo free radical levels.
    Type: Application
    Filed: October 8, 2002
    Publication date: February 27, 2003
    Applicant: MCW Research Foundation, Inc.
    Inventor: Ching-San Lai
  • Patent number: 6524564
    Abstract: The present invention relates to free-radically polymerizable, siloxane-containing urethane (meth)acrylates which comprise, in incorporated form, a) at least one compound which contains at least one active hydrogen atom and at least one free-radically polymerizable &agr;,&bgr;-ethylenically unsaturated double bond per molecule, b) at least one diisocyanate, c) at least one compound which contains two active hydrogen atoms per molecules, d) at least one compound which contains at least one active hydrogen atom and at least one siloxane group per molecule, to water-soluble or water-dispersible polymers which comprise these urethane (meth)acrylates in copolymerized form, to the use of these polymers, and to cosmetic compositions which comprise these polymers.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: February 25, 2003
    Assignee: BASF Aktiengesellschaft
    Inventors: Son Nguyen Kim, Axel Sanner, Volker Schehlmann
  • Patent number: 6506794
    Abstract: An aqueous dispersion comprising a halopropargyl compound (HPC) and a partially hydrolysed polyvinyl alcohol (PHPVA). The aqueous dispersions are useful for inhibiting the growth of micro-organisms on or in a medium, especially an industrial medium such as paint films, metal working fluids, wood, latices and plastic materials.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: January 14, 2003
    Assignee: Avecia Inc.
    Inventors: Emerentiana Sianawati, John Edward Yates
  • Patent number: 6500849
    Abstract: Novel 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols, intermediates and processes for the preparation thereof, and methods of reducing inflammation and cell proliferation, and relieving memory dysfunction, and inhibiting bacterial and fungal growth are disclosed.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: December 31, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: John Joseph Tegeler, Barbara Seavey Rauckman, Russell Richard Lee Hamer, Brian Scott Freed, Gregory Harold Merriman
  • Patent number: 6498188
    Abstract: Methods for the treatment of cancers or viral infections in mammals are disclosed that include administration of an N-chlorophenylcarbamate, or an N-chlorophenylthiocarbamate, or a salt thereof. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: December 24, 2002
    Assignee: The Procter & Gamble Company
    Inventor: James Berger Camden
  • Patent number: 6495538
    Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: December 17, 2002
    Assignee: Zinc Therapeutics, Canada Inc.
    Inventor: Henry Fliss
  • Publication number: 20020177583
    Abstract: Methods and compositions for altering the viability of cells, particularly cancers in animals and humans are disclosed. The compositions of the present invention are formed from a set of components comprising one or more of the following: a dithiocarbonyl, preferably dithiocarbamate, compound; a divalent metal ion; a modulator of cellular glutathione levels; and an inhibitor of the phosphorylation of choline. The compositions described herein induce a relatively selective and rapid effect on the viability of cancer cells by inducing a mixture of apoptotic and necrotic cell death, with the dominant pathway being apoptosis. Particularly preferred active compositions comprise all four components, although combinations of fewer components can be fully effective in certain tumors.
    Type: Application
    Filed: May 24, 2001
    Publication date: November 28, 2002
    Inventor: Zoltan Kiss
  • Publication number: 20020151540
    Abstract: The present invention provides a novel dithiocarbamamte disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.
    Type: Application
    Filed: January 11, 2002
    Publication date: October 17, 2002
    Applicant: Medinox, Inc.
    Inventors: Ching-San Lai, Vassil Vassilev
  • Patent number: 6444701
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: September 3, 2002
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria Ornella Tinti, Piero Chiodi, Arduino Arduini
  • Patent number: 6414019
    Abstract: Novel synergistic fungicidal compositions used for protecting seeds, plants and other vegetative material against fungi contain a mixture of one or more compounds selected from group A and one or more compounds selected from group B. Compounds from group A are selected from Beta-Amino butyric acid and its N-benzoyl-octyl ester derivatives. Compounds from group B are selected from the group of fosetyl aluminum, dimethomorph, a mixture of folpet and ofurace (45:5), folpet fencaramid (Bayer SZX), mancozeb, cymoxynil, methalaxyl, the single optical isomer of metalaxyl, a mixture of cymoxamil and mancozeb (4:1), copper sulfate, copper hydroxide, copper sulfate hydrate, azoxystrobin, and acidenzolar-s-methyl.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: July 2, 2002
    Assignee: Agrogene Ltd.
    Inventors: Yigal Cohen, Moshe Korat, Dan Zvi-Tov
  • Publication number: 20020082400
    Abstract: Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide duplexes of at least 20 base pairs that have significant binding activity-for human lupus anti-dsDNA autoantibodies.
    Type: Application
    Filed: December 29, 2000
    Publication date: June 27, 2002
    Inventors: Stephen M. Coutts, David S. Jones, Douglas Alan Livingston, Lin Yu
  • Patent number: 6407090
    Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for blocking apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: June 18, 2002
    Assignee: Zinc Therapeutics Canada, Inc.
    Inventor: Henry Fliss
  • Publication number: 20020045573
    Abstract: In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression.
    Type: Application
    Filed: October 1, 1999
    Publication date: April 18, 2002
    Inventor: CHING-SAN LAI
  • Patent number: 6369073
    Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: April 9, 2002
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Fabio Giannessi, Mauro Marzi, Patrizia Minetti, Francesco De Angelis, Maria Ornella Tinti, Piero Chiodi, Arduino Arduini
  • Patent number: 6344472
    Abstract: A fungicidal composition comprising a compound A having the formula: wherein M is an oxygen or sulphur atom, n is 0 and 1, and Y is a fluorine or chlorine atom or a methyl radical; and at least one fungicidal compound B. A method for preventing or controlling phytopathogenic fungi on crops by applying an effective and non-plant-poisonous amount of said compound on the exposed parts of the plants is also disclosed.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: February 5, 2002
    Assignee: Rhone-Poulenc, Inc.
    Inventor: Marie-Pascale Latorse
  • Patent number: 6344485
    Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: February 5, 2002
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker
  • Patent number: 6331531
    Abstract: Method for controlling harmful organisms in genetically modified cotton plants which contain a gene derived from Bacillus thuringiensis which encodes and expresses an insecticidally active protein, which comprises applying an insecticisally effective amount of one or more compounds from the following groups and a-f, described herein, to the plants, to their seeds or propagation stock and/or to the area in which they are cultivated. The method according to the invention makes it possible to reduce the application rate of crop protection agents which act synergistically with the transgenic plants, and also to increase and widen the efficacy of the transgenic plants, and therefore offers both economical and ecological advantages.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: December 18, 2001
    Assignee: Aventis CropScience GmbH
    Inventor: Manfred Kern
  • Patent number: 6329424
    Abstract: A phytomicrobicidal composition comprising such an amount of at least two active ingredient components that a synergistic effect is achieved, together with a suitable carrier material, wherein component I is a compound of the formula I in which: X is CH or N; R is CH3 or cyclopropyl; Y is H, F, Cl, Br, CF3, CF3O, propargyloxy; Z is H, F, Cl, CF3, CF3O; or Y and Z together are a methylenedioxy, a (difluoromethylene)dioxy, an ethylenedioxy, a (trifluoroethylene)dioxy or a benzo group; and wherein component II is a compound selected from the group consisting of II A) metalaxyl, II B) R-metalaxyl, II C) furalaxyl, II D) benalaxyl, II E) ofurace, II F) oxadixyl, II G) cymoxanil and II H) mancozeb.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: December 11, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gertrude Knauf-Beiter, Ronald Zeun
  • Patent number: 6309633
    Abstract: The invention provides a drug-oligomer conjugate having the following general formula: wherein D is a therapeutic drug moiety; H and H′ are each a hydrophilic moiety, independently selected from the group consisting of straight or branched PEG polymers having from 2 to 130 PEG subunits, and sugars; L is a lipophilic moiety selected from the group consisting of alkyl groups having 2-26 carbon atoms, cholesterol, adamantane and fatty acids; o is a number from 1 to the maximum number of covalent bonding sites on H; m+n+p together have a value of at least one and not exceeding the total number of covalent bonding sites on D for the —H′, —L and —H—L substituents; the H—L bond(s) are hydrolyzable and the D—L′ bond(s), when present, are hydrolyzable; the conjugate being further characterized by one of the following: (i) m is 0 and p is at least 1; (ii) n is 0 and p is at least 1; (iii) m and n are each 0 and p is at least 1; (iv) p is
    Type: Grant
    Filed: June 19, 1999
    Date of Patent: October 30, 2001
    Assignee: Nobex Corporation
    Inventors: Nnochiri Ekwuribe, Muthukumar Ramaswamy, Jayanthi Sethuraman Rajagopalan
  • Patent number: 6303649
    Abstract: A compound of formula (I), wherein R1 is carboxy or protected carboxy, R2 and R3 are each independently hydrogen, hydroxy, or protected hydroxy, R4 is hydrogen or halogen, R5 is aryl substituted with halogen, amino, hydroxy or protected hydroxy, R6 is aryl optionally substituted with halogen, amino, hydroxy or protected hydroxy, A1 and A2 are each independently lower alkylene, and (II) is (III), (IV), (V) or (VI) or its salt, process for preparing it, a pharmaceutical composition including it, and a use thereof.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: October 16, 2001
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kouji Hattori, Hiromichi Itani, Akira Tanaka, Toshifumi Shiraga
  • Publication number: 20010021378
    Abstract: There are described a flowable composition for controlling harmful insects and representatives of the order Acarina, comprising at least one pesticidally active compound, one or more signal substances selected from the group consisting of pheromones, kairomones and attractants, a UV absorber or a UV absorber mixture and, if appropriate, one or more additives selected from the group consisting of viscosity-regulating thickeners, fillers, solvents and other formulation auxiliaries,
    Type: Application
    Filed: February 22, 2001
    Publication date: September 13, 2001
    Inventors: Dieter Hofer, Max Angst, Pierre-Joseph Charmillot
  • Patent number: 6248762
    Abstract: When used in admixture with mancozeb, chlorothalonil, a copper salt, folpet, fluazinam or cymoxanil (it being possible for the latter to be used also together with one of the other five components), metalaxyl having a high R-enantiomer content of more than 70% by weight, or pure R-metalaxyl, exhibits a markedly increased fungicidal action against plant diseases as compared with a similar mixture in which metalaxyl is used in the form of the racemate.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: June 19, 2001
    Assignee: Syngenta Investment Corporation
    Inventors: Cosima Nuninger, John Edward Nicholas Goggin, Dino Sozzi
  • Patent number: 6172094
    Abstract: A composition comprising effective amounts of a) a carbamate of the formula I where X is CH or N, n is 0, 1 or 2 and R is halogen, C1-C4-alkyl or C1-C4-haloalkyl, it being possible for the radicals R to be different if n is 2, and b) a dithiocarbamate (II) selected from the group consisting of manganese ethylenebis(dithiocarbamate) (zinc complex) (IIa), manganese ethylenebis(dithiocarbamate) (IIb), zinc ammoniate ethylenebis(dithiocarbamate) (IIc) and zinc ethylenebis(dithiocarbamate) (IId) and optionally c) 1-(2-cyano-2-methoxyiminoacetyl)-3-ethylurea (III) H3CCH2—NHCONH—CO—C(CN)═NOCH3  (III) which exhibits a synergistically enhanced fungicidal effect is described.
    Type: Grant
    Filed: October 22, 1998
    Date of Patent: January 9, 2001
    Assignee: BASF Aktiengesellschaft
    Inventors: Bernd M{umlaut over (u)}ller, Hubert Sauter, Eberhard Ammermann, Gisela Lorenz, Siegfried Strathmann, Maria Scherer, Klaus Schelberger, Joachim Leyendecker
  • Patent number: 6124349
    Abstract: The present invention provides methods for producing pharmaceutical-grade particulate dithiocarbamates from secondary amines by vigorously contacting at least one secondary amine and a pharmaceutically acceptable diluent that is a solvent for the carbon disulfide, but not for the secondary amine in an inert gas atmosphere, cooling the mixture so as to precipitate the dithiocarbamate therefrom, and separating the precipitated dithiocarbamate from the cooled mixture. The preferred solvent contains absolute ethanol. In alternative embodiments, the invention further provides methods for purifying a dithiocarbamate to obtain a pharmaceutical-grade dithiocarbamate particulate from a dithiocarbamate feed and methods for producing a sterile pharmaceutical-grade dithiocarbamate from a dithiocarbamate feed.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: September 26, 2000
    Assignee: Medinox, Inc.
    Inventors: Vassil P. Vassilev, Wei-Cheng Liaw, Ching-San Lai
  • Patent number: 6114378
    Abstract: A fungicidal mixture comprisinga) an oxime ether of the formula I ##STR1## where the substituents have the following meaning: X is oxygen or amino (NH);Y is CH or N;Z is oxygen, sulfur, amino (NH) or C.sub.1 -C.sub.4 -alkylamino (N--C.sub.1 -C.sub.4 -alkyl);R' is C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -haloalkyl, C.sub.3 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -haloalkenyl, C.sub.3 -C.sub.6 -alkynyl, C.sub.3 -C.sub.6 -haloalkynyl, C.sub.3 -C.sub.6 -cycloalkylmethyl, or benzyl which may be partially or fully halogenated and/or may carry one to three of the following radicals: cyano, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -haloalkoxy and C.sub.1 -C.sub.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: September 5, 2000
    Assignee: BASF Aktiengesellschaft
    Inventors: Ruth Muller, Herbert Bayer, Hubert Sauter, Eberhard Ammermann, Gisela Lorenz, Siegfried Strathmann, Klaus Schelberger, Maria Scherer